<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759131</url>
  </required_header>
  <id_info>
    <org_study_id>EFC16295</org_study_id>
    <secondary_id>2020-000769-18</secondary_id>
    <secondary_id>U1111-1244-0558</secondary_id>
    <nct_id>NCT04759131</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A</brief_title>
  <acronym>XTEND-Kids</acronym>
  <official_title>A Phase 3 Open-label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients &lt;12 Years of Age With Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioverativ, a Sanofi company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      - To evaluate the safety of BIVV001 in previously treated pediatric subjects with hemophilia&#xD;
      A&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate the efficacy of BIVV001 as a prophylaxis treatment&#xD;
&#xD;
        -  To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes&#xD;
&#xD;
        -  To evaluate BIVV001 consumption for prevention and treatment of bleeding episodes&#xD;
&#xD;
        -  To evaluate the effect of BIVV001 prophylaxis on joint health outcomes&#xD;
&#xD;
        -  To evaluate the effect of BIVV001 prophylaxis on Quality of Life (QoL) outcomes&#xD;
&#xD;
        -  To evaluate the efficacy of BIVV001 for perioperative management&#xD;
&#xD;
        -  To evaluate the safety and tolerability of BIVV001 treatment&#xD;
&#xD;
        -  To assess the pharmacokinetics (PK) of BIVV001&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participants will be approximately 60 weeks (maximum 8 weeks for screening&#xD;
      and 52 weeks of treatment)&#xD;
&#xD;
      All participants completing or remaining at the end of study will be offered participation in&#xD;
      the planned extension trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of inhibitor development</measure>
    <time_frame>baseline to 52 weeks</time_frame>
    <description>The occurrence of inhibitor development (neutralizing antibodies directed against factor VIII [FVIII]) as determined via the Nijmegen modified Bethesda assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized bleeding rate (ABR) levels</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>Annualized bleeding rate (ABR) for treated, for untreated, for all bleeding episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized bleeding rate (ABR) by type of bleed</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>ABR by type of bleed such as spontaneous or traumatic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized bleeding rate (ABR) by location of bleed</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>ABR by location of bleed such as joint, muscle, internal, or skin/mucosa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who maintain FVIII activity above prespecified levels</measure>
    <time_frame>baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injection and dose of BIVV001 to treat a bleeding episode</measure>
    <time_frame>baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of bleeding episodes treated with a single injection of BIVV001</measure>
    <time_frame>baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of response to BIVV001 treatment of individual bleeding episodes</measure>
    <time_frame>52 weeks</time_frame>
    <description>Assessment of response to BIVV001 treatment of individual bleeding episodes based on the International Society on Thrombosis and Haemostasis (ISTH) 4-point response scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global assessment of the participant's response based on BIVV001 treatment</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>Physician's global assessment (PGA) of participant's response to BIVV001 treatment based on a 4-point response scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total annualized BIVV001 consumption</measure>
    <time_frame>baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Joint Bleeding Rate (AJBR)</measure>
    <time_frame>baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target joint resolution</measure>
    <time_frame>At week 52</time_frame>
    <description>Target joint resolution at week 52, based on ISTH criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemophilia Joint Health Score (HJHS) total score and domain scores</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>Change from baseline to week 52 in total score and domain scores (eg, swelling and strength) assessed by the HJHS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Haemophilia Quality of Life Questionnaire for Children (Haemo-QoL) total score</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>Changes in Haemophilia Quality of Life Questionnaire for Children (Haemo-QoL) total score from baseline to Week 52 (≥ 4 years old and parent proxy for all ages)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Haemophilia Quality of Life Questionnaire for Children (Haemo-QoL) physical health domain scores from</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>Changes in Haemophilia Quality of Life Questionnaire for Children (Haemo-QoL) physical health domain scores from baseline to Week 52 (≥ 4 years old and parent proxy for all ages)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigators' or Surgeons' assessment of participant's hemostatic response to BIVV001 treatment</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>Investigators' or Surgeons' assessment of participant's hemostatic response to BIVV001 treatment on the ISTH 4 point response for surgical procedures scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injections and dose to maintain hemostasis during perioperative period for major surgery</measure>
    <time_frame>baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total BIVV001 consumption during perioperative period for major surgery</measure>
    <time_frame>baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blood component transfusions used during perioperative period for major surgery</measure>
    <time_frame>baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of blood component transfusions used during perioperative period for major surgery</measure>
    <time_frame>baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated blood loss during perioperative period for major surgery</measure>
    <time_frame>baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with occurence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>Participants with ocurrence of adverse events (AEs) and serious adverse events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with occurrence of embolic and thrombotic events</measure>
    <time_frame>baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Maximum activity (Cmax)</measure>
    <time_frame>baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Elimination half-life (t1/2)</measure>
    <time_frame>baseline (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Total clearance (CL)</measure>
    <time_frame>baseline (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Total clearance at steady state (CLss)</measure>
    <time_frame>baseline (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter:dose-normalized area under the activity-time curve (DNAUC)</measure>
    <time_frame>baseline (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Area under the activity time curve (AUC)</measure>
    <time_frame>baseline (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Volume of distribution at steady state (Vss)</measure>
    <time_frame>baseline (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Mean residence time (MRT)</measure>
    <time_frame>baseline (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Incremental recovery (IR)</measure>
    <time_frame>baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Trough activity (Ctrough)</measure>
    <time_frame>baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Time above predefined FVIII activity levels</measure>
    <time_frame>baseline (day 1)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive weekly dose of BIVV001 for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efanesoctocog alfa (BIVV001)</intervention_name>
    <description>Pharmaceutical form:solution for injection Route of administration: Intravenous</description>
    <arm_group_label>Prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Participant must be younger than 12 years of age, at the time of signing the informed&#xD;
             consent&#xD;
&#xD;
          -  Severe hemophilia A defined as &lt;1 IU/dL (&lt;1%) endogenous FVIII as documented either by&#xD;
             central laboratory testing at Screening or in historical medical records from a&#xD;
             clinical laboratory demonstrating &lt;1% FVIII coagulant activity (FVIII:C) or a&#xD;
             documented genotype known to produce severe hemophilia A.&#xD;
&#xD;
          -  Previous treatment for hemophilia A (prophylaxis or on-demand) with any recombinant&#xD;
             and/or plasma-derived FVIII, or cryoprecipitate for at least 150 EDs for patients aged&#xD;
             6-11 years and above 50 EDs for patients aged &lt;6 years&#xD;
&#xD;
          -  Weight above or equal to 10 kg.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of hypersensitivity or anaphylaxis associated with any FVIII product.&#xD;
&#xD;
          -  History of a positive inhibitor (to FVIII) test defined as ≥0.6 BU/mL, or any value&#xD;
             greater than or equal to the lower sensitivity cut-off for laboratories with cut-offs&#xD;
             for inhibitor detection between 0.7 and 1.0 BU/mL, or clinical signs or symptoms of&#xD;
             decreased response to FVIII administrations. Family history of inhibitors will not&#xD;
             exclude the participant.&#xD;
&#xD;
          -  Positive inhibitor test result, defined as ≥0.6 BU/mL at Screening.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3833</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400002</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400015</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400008</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400012</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400003</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-4306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360002</name>
      <address>
        <city>South Brisbane</city>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360001</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0560002</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0560001</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240004</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240003</name>
      <address>
        <city>London</city>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240002</name>
      <address>
        <city>Ottawa</city>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240001</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500004</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500001</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500003</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500002</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760001</name>
      <address>
        <city>Frankfurt Am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760002</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3720001</name>
      <address>
        <city>Dublin</city>
        <zip>D12 N512</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5280002</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240002</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240001</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7520001</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7560001</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1580001</name>
      <address>
        <city>Taichung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1580003</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1580004</name>
      <address>
        <city>Taipei</city>
        <zip>11031</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920001</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8260001</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 13, 2021</study_first_submitted>
  <study_first_submitted_qc>February 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

